These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 22244809)
1. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers. Sturm S; Seiberling M; Weick I; Paehler A; Funk C; Ruf T Clin Ther; 2012 Feb; 34(2):420-9. PubMed ID: 22244809 [TBL] [Abstract][Full Text] [Related]
2. No evidence of QT prolongation with supratherapeutic doses of aleglitazar. Sturm S; Bentley D; Jordan P; Russell-Yarde F; Ruf T J Cardiovasc Pharmacol; 2012 Mar; 59(3):288-97. PubMed ID: 22113345 [TBL] [Abstract][Full Text] [Related]
3. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. Sanwald-Ducray P; Liogier D'ardhuy X; Jamois C; Banken L Clin Pharmacol Ther; 2010 Aug; 88(2):197-203. PubMed ID: 20336066 [TBL] [Abstract][Full Text] [Related]
5. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Herz M; Gaspari F; Perico N; Viberti G; Urbanowska T; Rabbia M; Wieczorek Kirk D Int J Cardiol; 2011 Sep; 151(2):136-42. PubMed ID: 20837369 [TBL] [Abstract][Full Text] [Related]
6. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777 [TBL] [Abstract][Full Text] [Related]
7. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects. Sanwald-Ducray P; Jamois C; Banken L J Cardiovasc Pharmacol; 2014 Feb; 63(2):152-7. PubMed ID: 24157957 [TBL] [Abstract][Full Text] [Related]
8. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection. Wang L; Zhang D; Swaminathan A; Xue Y; Cheng PT; Wu S; Mosqueda-Garcia R; Aurang C; Everett DW; Humphreys WG Drug Metab Dispos; 2006 Mar; 34(3):427-39. PubMed ID: 16381667 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus. Cavender MA; Lincoff AM Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327 [TBL] [Abstract][Full Text] [Related]
10. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415 [TBL] [Abstract][Full Text] [Related]
11. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers. Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Blight AR; Henney HR Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905 [TBL] [Abstract][Full Text] [Related]
13. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes. Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796 [TBL] [Abstract][Full Text] [Related]
15. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281 [TBL] [Abstract][Full Text] [Related]
16. Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite. Bopst M; Atzpodien EA Regul Toxicol Pharmacol; 2017 Jun; 86():107-116. PubMed ID: 28274810 [TBL] [Abstract][Full Text] [Related]
17. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus. Lecka-Czernik B IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527 [TBL] [Abstract][Full Text] [Related]
18. Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards. Zhang D; Zhang H; Aranibar N; Hanson R; Huang Y; Cheng PT; Wu S; Bonacorsi S; Zhu M; Swaminathan A; Humphreys WG Drug Metab Dispos; 2006 Feb; 34(2):267-80. PubMed ID: 16280454 [TBL] [Abstract][Full Text] [Related]
19. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Kim JW; Kim JR; Yi S; Shin KH; Shin HS; Yoon SH; Cho JY; Kim DH; Shin SG; Jang IJ; Yu KS Clin Ther; 2011 Nov; 33(11):1819-30. PubMed ID: 22047812 [TBL] [Abstract][Full Text] [Related]
20. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. Koomen JV; Heerspink HJL; Schrieks IC; Schwartz GG; Lincoff AM; Nicholls SJ; Svensson A; Wedel H; Weichert A; Grobbee DE; Stevens J Diabetes Obes Metab; 2020 Jan; 22(1):30-38. PubMed ID: 31468659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]